DelveInsight’s, “Advanced Endometrial Cancer Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Advanced Endometrial Cancer pipeline landscape. It covers the Advanced Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Endometrial Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Advanced Endometrial Cancer Pipeline Report to explore emerging therapies, key Advanced Endometrial Cancer Companies, and future Advanced Endometrial Cancer treatment landscapes @ Advanced Endometrial Cancer Pipeline Outlook Report
Key Takeaways from the Advanced Endometrial Cancer Pipeline Report
- In May 2025, Mario Negri Institute for Pharmacological Research announced a Phase Ia study of Atezolizumab (NCT01375842) monotherapy in relapsed endometrial cancer were reported as abstract at ASCO 2017. Fifteen patients were evaluated for safety and efficacy with a minimum follow-up of 11.2 months. No G4-5 related AEs occurred. Regarding efficacy ORR was 13% [2/15] by RECIST. Atezolizumab seemed to have a favorable safety profile, with durable clinical benefit in some patients. Further studies with atezolizumab are warranted given its promising results in advanced endometrial cancer and the limited efficacy of current treatment options.
- In May 2025, AstraZeneca conducted a phase IIIb study assessing the safety profile of durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC as the primary endpoint.
- In May 2025, Artios Pharma Ltd. announced a study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
- In May 2025, Seagen announced a study is being done to see if DV works to treat different types of solid tumors that express HER2. It will also test how safe the drug is for participants. This trial will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
- DelveInsight’s Advanced Endometrial Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Advanced Endometrial Cancer treatment.
- The leading Advanced Endometrial Cancer Companies such as Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
- Promising Advanced Endometrial Cancer pipeline therapies such as Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
Discover how the Advanced Endometrial Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Advanced Endometrial Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Endometrial Cancer Clinical Trials and Studies
Advanced Endometrial Cancer Emerging Drugs
- Retifanlimab: Incyte Corporation
Retifanlimab (formerly INCMGA0012), an investigational intravenous PD-1 inhibitor, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell carcinoma of the anal canal (SCAC); and in combination with platinum-based chemotherapy for patients with non-small cell lung cancer and SCAC.
- Trastuzumab duocarmazine (SYD985): Byondis
The most advanced compound in the company’s pipeline is trastuzumab duocarmazine (US non-proprietary name [vic-]trastuzumab duocarmazine). This investigational anti-HER2 ADC, targets a broad range of HER2-expressing cancers such as (metastatic) breast, gastric, bladder (urothelial) and uterine (endometrial) cancer. Trastuzumab duocarmazine could be used in patients where other (anti-HER2) treatments have failed, reflecting our philosophy of developing new, innovative medicines for relentless cancers. Trastuzumab duocarmazine is Byondis’ frontrunner ADC. The antibody, trastuzumab, can bind to a specific protein, HER2 (Human Epidermal growth factor Receptor 2) on the cell surface of tumor cells in many different tumor types. The linker-drug in trastuzumab duocarmazine is vc-seco-DUBA.
The Advanced Endometrial Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Endometrial Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Endometrial Cancer Treatment.
- Advanced Endometrial Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Advanced Endometrial Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Endometrial Cancer market.
Get a detailed analysis of the latest innovations in the Advanced Endometrial Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Advanced Endometrial Cancer Unmet Needs
Advanced Endometrial Cancer Companies
Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
Advanced Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Advanced Endometrial Cancer Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Download DelveInsight’s latest report to gain strategic insights into upcoming Advanced Endometrial Cancer Therapies and key Advanced Endometrial Cancer Developments @ Advanced Endometrial Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Advanced Endometrial Cancer Pipeline Report
- Coverage- Global
- Advanced Endometrial Cancer Companies- Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
- Advanced Endometrial Cancer pipeline therapies- Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
- Advanced Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Advanced Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Advanced Endometrial Cancer drug development? Find out in DelveInsight’s exclusive Advanced Endometrial Cancer Pipeline Report—access it now! @ Advanced Endometrial Cancer Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Advanced Endometrial Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced Endometrial Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Selinexor: Karyopharm Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Retifanlimab: Incyte Corporation
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Alsevalimab: Five Prime Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced Endometrial Cancer Key Companies
- Advanced Endometrial Cancer Key Products
- Advanced Endometrial Cancer- Unmet Needs
- Advanced Endometrial Cancer- Market Drivers and Barriers
- Advanced Endometrial Cancer- Future Perspectives and Conclusion
- Advanced Endometrial Cancer Analyst Views
- Advanced Endometrial Cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-endometrial-cancer-pipeline-insight